“Emergency Off-Switch” for psychedelics?

MindMed $MMED beings study on “LSD neutralizer technology”

I.e., the 5-HT2A antagonist ketanserin: psychedelicreview.com/compound/ketan…

1/4
Patent application first announced on April 21, 2020

As @psyscireview subsequently wrote: “Few Details of the Invention Are Available”

18 months after filing, the application—& those details—will become public

~ October 2021

psychedelicreview.com/stopping-bad-l…

2/4
“LSD neutralizer technology”—is it possible, patentable, profitable?

Last year, from @D__Nickles: psymposia.com/magazine/rahn-…

Today, more insights from @mattbagg:

3/4
Is terminating “bad trip” in one’s best interest?

Therapists can “make these rough journeys fruitful rather than horrifying…

Often, reminding people to ‘let go’ & be open to their experiences prevents them from developing a mindset of resistance”

psychedelicreview.com/the-problem-an…

4/4

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Graham Pechenik

Graham Pechenik Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @calyxlaw

18 Feb
How much is a psilocybin patent application worth?

PharmaTher $PHRM sells psilocybin program to Revive Therapeutics $RVV

Includes full rights to PharmaTher’s psilocybin IP:

Pre-clinical work + three psilocybin provisional applications

1/4
Purchase price for PharmaTher’s psilocybin IP:

–$3 million in cash

–$4 million in securities

–up to $3 million in milestone payments

–“low single digit royalty” on future net sales

2/4
More on PharmaTher’s:

Psilocybin combination therapies:

Psilocybin in treatment of cancer:

Microneedle delivery technology, which it retains after the sale:

3/4
Read 4 tweets
16 Feb
Controlled release psilocybin + cannabinoid formulations?

New published patent application on multilayer tablets & capsules w psilocybe-derived + cannabis-derived compounds

Filed by Tassili Life Sciences, acquired last yr by Champignon Brands

patentscope.wipo.int/search/en/deta… $SHRM

1/ ImageImageImage
Application claims compositions of “psilocybe-derived agent and a cannabis-derived agent”

”formulated in multiple layers to release the psilocybin-derived agent and the cannabis-derived agent at multiple different times, dosages and/or locations in a subject during dosing”

2/ Image
Application asserts controlled release formulations of psilocybin + CBD can result in “multiple chemical-induced high/low shocks”

"useful in eliciting short or long term traumatic experience suppression in similar fashion to electroshock therapy without memory eradication”

3/ ImageImage
Read 6 tweets
23 Dec 20
Canopy Growth sues GW Pharmaceuticals:

Complaint for patent infringement filed on 12/22 in Texas

“This dispute relates to GW’s continued, unauthorized use of Canopy’s patented processes for extracting cannabidiol from cannabis plant material.”

1/

$CGC $GWPH #cannabispatents
Canopy alleges infringement of one patent:

US Patent No. 10,870,632 “Process For Producing An Extract Containing Tetrahydrocannabinol And Cannabidiol From Cannabis Plant Material, And Cannabis Extracts”

Patent issued 12/22—same day complaint filed

pdfpiw.uspto.gov/.piw?Docid=108…

2/
Canopy got the patent in its acquisition of Germany’s C3 Cannabinoid Compound Company, founded by herbal medicine manufacturer Bionorica SE

It is part of a patent family dating back to a German application filed on October 17, 2000

It relates to CO2 extraction of THC & CBD

3/
Read 9 tweets
17 Dec 20
Deuterated DMT analogs?

New patent application by Small Pharma published today.

The “invention provides compositions and methods which enable a finely tuned single dose to maintain a patient in full dissociation from the external world, referred to herein as ‘DMT space.’”

1/ Image
In particular, the invention takes advantage of “the kinetic isotope effect” exhibited by deuterated DMT analogs “in order to modify, controllably, the pharmacokinetic profile of N,N-DMT, thereby permitting more flexible therapeutic application.”

pdfaiw.uspto.gov/.aiw?PageNum=0…

2/ Image
“Deuterated” means that one or more hydrogen atoms in DMT are replaced by its heavier stable isotope deuterium. Because of the “kinetic isotope effect,” deuterated drugs may have significantly lower rates of metabolism and a longer half-life.

en.wikipedia.org/wiki/Deuterate…

3/ Image
Read 9 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!